Drug intelligence / Profile preview

mianserin

Development stage
Phase 4
Lead developer
Organon
Modality
Small Molecules
Administration
Oral
01

Overview

Mianserin is a tetracyclic antidepressant used primarily for the treatment of depression and anxiety. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). Its mechanism of action involves blocking alpha-adrenergic receptors and histamine H1 receptors while also interacting with certain serotonin receptors in the central nervous system. Mianserin has strong antihistaminic and hypnosedative effects but minimal anticholinergic activity. It weakly inhibits norepinephrine reuptake and stimulates norepinephrine release. The drug is often used when sleep disturbances are present in depression or for patients who may be more susceptible to side effects from other antidepressants[1][2][5].

Brand names
TolvonLantanonLerivonMiagenMianserin RemedicaPrevalinaSeridacAthymilBonserinDepnonDeprexolet
Other names
mianserinummiansérinemianserinamiansegen
02

Targets

ADRA2C (α2C)HRH1 (Histamine H1 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)ADRA2B (α2B)ADRA2A (α2A)HRH4 (Histamine H4 receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on mianserin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mianserin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call